KORU Medical Systems develops, manufactures, and commercializes large-volume subcutaneous infusion solutions for the drug delivery market. The company's primary product line is the FREEDOM Infusion System, which includes the FREEDOM60 Syringe Driver, FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing. These mechanical, battery-free devices are designed for patient self-administration of subcutaneous drugs, primarily immunoglobulin therapies for Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), as well as other indications such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and generalized myasthenia gravis. KORU serves domestic and international markets through direct sales and medical device distributors, supplying pharmaceutical companies, specialty pharmacies, and home infusion providers. The company also generates revenue from non-recurring engineering services and clinical trial support for biopharmaceutical partners developing new subcutaneous therapies. Founded in 1980, KORU operates under FDA quality and regulatory standards and international quality system management requirements.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage korumedical.com
Sector Healthcare IR page investors.korumedical.com
Tags
subcutaneous infusion, syringe drivers, immunoglobulin therapy, drug delivery systems, home infusion, medical needles, flow rate tubing, biopharmaceutical services, clinical trial support, FREEDOM Infusion System, FREEDOM60 Syringe Driver, FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, Precision Flow Rate Tubing, Cutaquig, Cuvitru, Hizentra, Xembify, Empaveli, Aspaveli, Gammagard Liquid, RYSTIGGO, HyQvia
Press page investors.korumedical.com/news-events/press-releases

Metrics

Valuation  
Market cap $ 167.52M
Market cap (USD) $ 167.52M
P/E -36.30
PEG —
P/BV 9.28
P/S 3.71
P/OCF 120.43
P/FCF 215.69
Dividend yield —
Turnover / mcap —
Returns  
ROE -15.6%
ROI -32.0%
ROIC -27.0%
Profit margin -6.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 36
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007
Revenue 41.127M 33.646M 28.518M 27.896M 23.49M 24.176M 23.163M 17.354M 12.294M 12.247M 11.245M 8.699M 7.764M 6.391M 4.921M 3.439M 2.348M
Net profit -2.638M -6.067M -13.741M -8.661M -4.563M -1.212M 564.349K 910.57K -534.999K 782.864K 753.117K 703.429K 725.763K 815.893K 704.085K 1.031M —
Free cash flow -470.112K -1.617M -5.676M -8.166M -4.666M -1.664M 119.446K 1.183M -534.741K 1.793M 234.686K 765.702K 221.223K 324.366K 827.943K 464.797K 79.056K

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2008 FY 2007
Share price 5.81 3.85 2.46 3.57 3 6.02 6.53 1.64 — — — — — — — — —
Price performance 12m 0.51 0.57 -0.31 0.19 -0.5 -0.08 2.98 — — — — — — — — — —

Filed figures

Figure Feb 2017 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.5M 1.86M 1.43M 3.23M 2.57M 3.59M 3.56M 4.05M 5.72M 6.21M
↳ YoY growth +11.2% -23.4% +126.8% -20.5% +39.6% -0.9% +13.7% +41.4% +8.6%
↳ 5y CAGR +11.2% +13.8% +23.2% +12.1% +19.3%
Lease liabilities (USD) — — — 381,676 239,492 95,553 4.49M 4.13M 3.72M 3.5M
Cash and deposits (USD) 3.31M 3.97M 3.74M 5.87M 27.3M 25.3M 17.4M 11.5M 9.58M 8.87M
Intangible assets (USD) 426,943 483,821 632,156 807,135 843,587 808,813 787,182 754,361 730,279 684,841
Right-of-use assets (USD) — — — 373,734 236,846 95,553 3.79M 3.51M 2.97M 2.96M
Cash flow detail
Operating cash flow (USD) -331,616 — 1.48M 320,620 -743,323 -4.32M -5.4M -4.89M -319,718 462,405
Purchases of property, plant and equipment (USD) -203,125 — -297,018 -201,174 -920,604 -346,178 -2.76M -782,949 -1.3M -932,517
Purchases of intangible assets (USD) -212,008 — -184,148 -224,365 -140,548 -29,056 -40,512 -31,648 -44,115 -23,973
Change in receivables (cash effect) (USD) -132,490 — 475,662 -1.8M 669,743 -1.02M 34,002 -486,327 -1.68M -489,199
Change in inventories (cash effect) (USD) -313,426 — -445,198 -284,598 -4.44M 723,434 -298,529 2.92M 677,632 -874,462
Change in payables (cash effect) (USD) 464,664 — -900 119,158 52,264 602,613 1.16M -1.42M 674,776 617,504
Share buybacks (cash effect) (USD) — — — -2,820 — — — — — —
Interest paid (cash effect) (USD) -1,886 — — -342 -27,736 -13,241 -28,490 -50,832 -71,934 -55,546
Income taxes paid (cash effect) (USD) -194,470 — -378,000 -130,879 -321,983 -1,903 — -3,160 — -14,850
Share-based compensation (USD) 205,486 — 366,081 1.2M 1.62M 2.71M 3.08M 2.77M 2.62M 2.71M
Operating cash flow before change in receivables (USD) -199,126 — 1M 2.12M -1.41M -3.3M -5.44M -4.41M 1.36M 951,604
Free cash flow (OCF - PPE - intangibles) (USD) -746,749 — 998,496 -104,919 -1.8M -4.69M -8.21M -5.71M -1.66M -494,085
Income detail
Research and development expense (USD) 237,486 — 241,124 740,475 1.3M 2.47M 4.96M 5.74M 5.26M 4.39M
↳ 5y CAGR +21.3% +88.5% +48.0% +27.6%
Provision for credit losses (USD) -19,360 — -39,567 — — — — — — —
Credit cost ratio (credit losses / average receivables) (%) 1.4% — 2.4% — — — — — — —
Reported May 5, 2017 Mar 5, 2018 Mar 5, 2019 Mar 23, 2021 Mar 23, 2021 Mar 2, 2022 Mar 8, 2023 Mar 13, 2024 Mar 12, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MAHWAH, NJ – November 10, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 and Recent Highlights

● Net revenues grew 11% over the prior year period to $11.6 million; year to date net revenues grew 17% to $35.4 million

● Gross profit grew 20% over the prior year period to $7.5 million, driven by gross margin improvement from 60.2% to 65.2%

● Net income improved by $1.0 million to $0.2 million compared to a net loss of $0.8 million in prior year period

● Adjusted EBITDA increased to $1.3 million from $0.1 million in the prior year period

● Signed two new sales and distribution agreements with partners in Europe and Africa, expanding our geographic footprint internationally

● Revising full-year 2026 revenue guidance to $48.0 - $48.5 million, representing year-over-year growth of 17% - 18%, compared to the previous guidance range of $47.5 - $48.5 million.

October 20, 2026 4:05 pm EDT Download as PDF

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2026 financial results on Tuesday, November 10, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Conference Call and Webcast Details

The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on the News/Events

page of the Investors section of KORU Medical’s website at www.korumedical.com

. The archived webcast will be available for six months.

Prompts

KORU Medical Systems, Inc. (ticker KRMD), listed in United States.

Company History

Date Change Detail
Jun 28, 2022 Renamed REPRO MED SYSTEMS INC → KORU MEDICAL SYSTEMS, INC.

ETFs Holding KORU Medical Systems, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.07% 942 $ 3,956.40 Jun 30, 2026
FEAC 0.05% 3,119 $ 13.1K Jun 30, 2026
DFSU 0.00% 3,240 $ 11.956K Nov 12, 2026
DCOR 0.00% 3,506 $ 12.937K Nov 12, 2026